|
 |
 Home > Available Issues |
|
|
 Original Articles |
| In Vitro Activities of LY303366 against Clinical Isolates of Candida spp.,
Cryptococcus neoformans and Aspergillus spp. |
| Kyungwon Lee, M.D., Dongeun Yong, M.D., Hee Bong Shin, M.D.,
Young Ah Kim, M.D. and Yunsop Chong, M.D. |
| Department of Clinical Pathology and Research Institute of Bacterial Resistance,
Yonsei University College of Medicine, Seoul, Korea |
Vol.32 Num.4 (p274~279)
|
|
|
Background:Fungal infection became more prevalent with the increase of compromised patients, requiring less toxic potent antifungal agents. LY303366, a new semisynthetic antifungal agent of echinocandin class, was reported to be active against Candida spp. and filamentous fungi.
Methods:In vitro activities of LY303366 were determined against clinical isolates of fungi by NCCLS broth microdilution test using RPMI 1640 medium.
Results:MIC90s of LY303366 were 0.03 μg/mL for C. albicans, 2 μg/mL for C. parapsilosis, 0.12 μg/mL for C. tropicalis. LY303366 was more active against C.albicans and C. tropicalis than amphotericin B, 5-fluorocytosine, or fluconazole. It was less active than other agents against C. neoformans. MIC range of LY303366 against Aspergillus spp. was 8->16 μg/mL.
Conclusion:Very high in vitro activity of LY303366 against recent clinical isolates of Candida spp. including fluconazole resistant ones, suggests its usefulness for the treatment of candidal infections. |
|
|
Keywords : Antifungal activity, LY303366, C. albicans, C. neoformans, Aspergillus spp. |
|
|
|
|
|
|
|
|
